Recently, HHLA2 was reported to be widely expressed in patients with PD-1-negative NSCLC, which suggests that HHLA2 might be a promising therapeutic target for patients who do not respond to PD-1 pathway blockade (67). Here, HHLA2 is linked to non-small cell lung carcinoma.